CORRECTION article

Front. Pharmacol., 07 September 2022

Sec. Pharmacology of Anti-Cancer Drugs

Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.964540

Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer

  • 1. Department of Thoracic Surgery, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China

  • 2. Department of Thoracic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

  • 3. Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

  • 4. Department of Oncology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China

Article metrics

View details

9

Citations

1,3k

Views

595

Downloads

In the published article, there was an error in the author list. Author Xing Feng was erroneously listed as corresponding author. The corrected author list appears below:

“Xing Feng1,2, Xiaoling Xiong3 and Shenglin Ma4*

*Correspondence: Shenglin Ma, mashenglin0607@163.com”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

non-small cell lung cancer, targeted therapy, immunotherapy, photothermal therapy, cGAS-STING

Citation

Feng X, Xiong X and Ma S (2022) Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer. Front. Pharmacol. 13:964540. doi: 10.3389/fphar.2022.964540

Received

08 June 2022

Accepted

09 August 2022

Published

07 September 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Shenglin Ma,

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics